MGF 5mg/vial 1 Vial by Bio-Peptide

Usage

1. Allow the Bio-Peptide MGF vial to reach room temperature before handling — do not inject cold lyophilised or reconstituted peptide.
2. Using a sterile 1 mL insulin syringe, draw 1–2 mL of bacteriostatic water and inject it slowly down the inner wall of the vial; swirl gently (never shake) until the powder is fully dissolved.
3. Calculate your target dose volume: for a 5 mg vial reconstituted in 1 mL, every 0.1 mL equals 0.5 mg (500 mcg); adjust the reconstitution volume to the dose precision you need.
4. Draw the calculated volume with a fresh insulin syringe immediately after your resistance-training session — the post-exercise window for satellite-cell responsiveness is short with native MGF.
5. Administer via intramuscular injection into the trained muscle group, or subcutaneously near the worked area; rotate injection sites between sessions to minimise localised irritation.
6. Seal the reconstituted vial, store upright in a refrigerator at 2–8 °C away from light, and discard any unused solution after 28 days or immediately if the solution appears cloudy or contains visible particles.

Warnings

Frequently asked questions

What exactly is Mechano Growth Factor and how does it differ from regular IGF-1?

Mechano Growth Factor is a locally acting splice variant of IGF-1 produced specifically in mechanically stressed muscle fibres, not the systemic liver-derived IGF-1 that circulates throughout the body. Its E-domain peptide signals satellite cells at the site of micro-damage, driving localised repair and hypertrophy rather than whole-body anabolic effects. This paracrine, tissue-specific mechanism is what distinguishes MGF from conventional IGF-1 isoforms.

When is the optimal window to inject native MGF after a training session?

Native MGF's estimated plasma half-life is under 30 minutes, so research protocols typically target administration within 15–30 minutes post-workout to coincide with the peak window of satellite-cell activation triggered by mechanical damage. Delayed injection beyond one hour may fall outside the period of maximal satellite-cell responsiveness to the MGF E-domain signal, reducing the hypothesised amplification effect on endogenous repair.

What does PEGylation do to MGF and why does it matter for dosing schedules?

PEGylation attaches polyethylene glycol chains to the MGF peptide backbone, shielding it from proteolytic breakdown and extending plasma half-life from under 30 minutes to an estimated 48–72 hours. This dramatically changes dosing logistics: PEG-MGF can be injected less frequently and does not demand the same strict post-workout timing that native MGF requires, making it more practical for protocols where precise injection windows are difficult to maintain.

How do you reconstitute a Bio-Peptide MGF 5mg vial and store it correctly?

Add bacteriostatic water (typically 1–2 mL) slowly down the inside wall of the vial — never shake; swirl gently until the lyophilised powder dissolves completely. Once reconstituted, store the vial upright in a refrigerator at 2–8 °C, away from light. Use within 28 days of reconstitution. Discard any remaining solution showing cloudiness or particulate matter.

What syringe type is recommended for injecting reconstituted MGF and why?

Insulin syringes (typically 28–31 gauge, 0.5 mL or 1 mL capacity) are the standard choice for reconstituted MGF because their fine gauge minimises injection-site trauma and allows precise small-volume measurements. For a 5 mg vial reconstituted in 1 mL of bacteriostatic water, each 0.1 mL drawn equals 0.5 mg — simplifying dose calculation. Intramuscular or subcutaneous injection sites should be rotated to avoid localised irritation. (2) angle_used

Manufacturer

Bio-Peptide's commercial identity was constructed around a constraint that is easier to describe than to sustain at scale: every compound the company releases — irrespective of molecular complexity — must clear two externally commissioned analytical tests before the product is eligible for labelling or distribution. That constraint was not adopted in response to market pressure; it was embedded as a structural prerequisite before the company entered commercial operation. For MGF, a short-chain splice-variant peptide whose sequence fidelity is critical to its proposed mechanism of action, that two-checkpoint framework carries particular weight. The first checkpoint is an HPLC (High-Performance Liquid Chromatography) analysis commissioned from an independent third-party laboratory — tasked specifically with confirming that the MGF E-domain peptide sequence matches the specified structure and that purity levels meet release thresholds. The second checkpoint is a LAL (Limulus Amebocyte Lysate) endotoxin assay, which certifies that microbiological contamination is within injection-grade limits. Both results are documented per batch, and that documentation travels with the product through distribution. GMP-aligned manufacturing conditions govern the upstream production environment in which these vials are prepared — meaning the two external tests are the final gate of a quality architecture, not a patch applied to an otherwise uncontrolled process.